Another large Bacil Pharma shareholder sells 5.57% stake
Manubhai Amrutlal Shah reduced holding to 12.77% on June 10. It's the second substantial open-market sale in a week for the zero-revenue nano-cap.
— 6 earlier stories on Bacil Pharma Ltd. →What's new
- Manubhai Shah sold 5.57% of Bacil Pharma via open market on June 10.
- His stake dropped from 18.34% to 12.77%.
- Follows a 2.27% sale by another non-promoter just days earlier.
Why this matters
For a company with zero operating revenue and a ₹63 crore market cap, two substantial open-market exits in a week signal that the largest shareholders are losing patience. The stock may face pressure as retail holders question the thesis.
What we're watching
- Whether more non-promoter holders follow suit.
- Any update on Bacil Pharma's business plans or lack thereof.
- Market reaction in the coming sessions.
The full read
Manubhai Amrutlal Shah sold 5.57% of Bacil Pharma in a single day, cutting his stake from 18.34% to 12.77%. That makes two substantial open-market exits in a week. Nikita Patel sold 2.27% days earlier. Between them, Bacil Pharma's largest non-promoter holders have cut their collective exposure by almost 8% of the company's equity. For a nano-cap with ₹63 crore market cap and zero operating revenue. That is a flashing signal. The company's latest quarter reported sales of ₹0 crore and a tiny net profit of ₹1 crore, likely from non-operating items. The pattern is clear: the shareholders who know the business best are leaving. Retail investors who bought the story of a pharma turnaround are now holding a company without revenue and with its biggest backers heading for the exits.
Questions answered
- Why is a non-promoter selling such a large chunk of Bacil Pharma?
- The company has zero operating revenue and minimal assets; the sale suggests reduced conviction among substantial holders. Manubhai Shah sold 5.57% in one day.
- How much stake does Manubhai Amrutlal Shah still hold?
- 12.77% as of June 10, down from 18.34%.
- Is this the first such sale by a major shareholder?
- No. Just days earlier, Nikita Patel sold 2.27% of the company, reducing her stake to 17%.
- What is Bacil Pharma's financial condition?
- It's a nano-cap with ₹63 cr market cap, zero operating revenue in recent periods, and a net profit of ₹1 cr in the March 2026 quarter (likely from non-operating items).
- Does this sale have to be reported to SEBI?
- Yes, as a substantial shareholder (holding >10%) under SAST regulations. The filing was made on June 12.
- What does this mean for the stock price?
- Two large open-market sales in a week could pressure the stock, but the company's tiny float and low liquidity may amplify moves.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 13 Jun 2026 · 12:17 PM IST Another large Bacil Pharma shareholder sells 5.57% stake
- today Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
- 1d ago Bacil Pharma board to mull fundraising options on June 26
- 6d ago Bacil Pharma proposes R&D arm, but numbers are missing
- 13d ago Nikita Patel cuts Bacil Pharma stake to 17% in open-market sale